Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Recurrent Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00096200
What this trial is testing

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Ended earlyNCT04377087
What this trial is testing

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sarah E Taylor 3
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Early research (Phase 1)Study completedNCT03704467
What this trial is testing

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 3
Not applicableStudy completedNCT05512676
What this trial is testing

Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum

Who this might be right for
Ovarian NeoplasmChemotherapeutic ToxicityChemotherapy Effect+2 more
Oslo University Hospital 40
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Not applicableStudy completedNCT00368420
What this trial is testing

Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
AGO Study Group 122
Testing effectiveness (Phase 2)Study completedNCT00316173
What this trial is testing

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerNeoplasms, Ovarian
GlaxoSmithKline 77
Large-scale testing (Phase 3)Not Yet RecruitingNCT07821606
What this trial is testing

Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Platinum-sensitive Recurrent Ovarian Cancer
Hansoh BioMedical R&D Company 460
Testing effectiveness (Phase 2)Study completedNCT01033292
What this trial is testing

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sanofi 43
Testing effectiveness (Phase 2)Study completedNCT00086892
What this trial is testing

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT01663857
What this trial is testing

A Study LY2228820 for Recurrent Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Eli Lilly and Company 118
Testing effectiveness (Phase 2)UnknownNCT05965141
What this trial is testing

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Who this might be right for
Ovarian Cancer
Second Affiliated Hospital of Guangzhou Medical University 38
Early research (Phase 1)Study completedNCT03213964
What this trial is testing

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota 10